**Common variants in Alzheimer’s disease: Novel association of six genetic variants with AD and risk stratification by polygenic risk** **scores**

**Supplementary Information**

***Supplementary Methods***

**GR@ACE GWAS genotyping**

DNA was extracted from peripheral blood according to standard procedures using the Chemagic system (Perkin Elmer). Samples reaching DNA concentrations of > 10ng/µl and presenting high integrity were included for genotyping. Cases and controls were randomised across sample plates to avoid batch effects.

The genotyping array is an adaptation of the Axiom Biobank Genotyping Array but also contains population-specific rare variations observed in the Spanish population. DNA samples were genotyped according to the manufacturer’s instructions (Axiom™ 2.0 Assay Manual Workflow). The Axiom 2.0 assay interrogates biallelic SNPs and simple indels in a single assay workflow. Starting with 200 ng of genomic DNA, the samples were processed through a manual target preparation protocol, followed by automated processing of the array plates in the GeneTitan Multi-Channel (MC) instrument. Target preparation involved DNA amplification, fragmentation, purification and resuspension of the target in a hybridisation cocktail. The hyb-ready targets were then transferred to the GeneTitan MC instrument for automated, hands-free processing including hybridisation, staining, washing and imaging. CEL files were generated using the GeneTitan MC instrument. Quality control was performed for samples and plates using the Affymetrix power tool (APT) 1.15.0 software following the Axiom Data Analysis Workflow. Sample quality was determined based on the resolution of AT and GC channels in a group of non-polymorphic SNPs (resolution > 0.82). Samples with a call rate greater than 97% and plates with an average call rate above 98.5% were included for final SNP calling. Samples were jointly called. Markers passing all QC tests were used in downstream analysis (NSNPs = 729,868; 95.4%) using the SNPolisher R package (Thermo Fisher). To assess the sample genotyping concordance, we intentionally re-sampled 200 samples and determined a concordance rate of 99.5%.

**Regional plots and Manhattan/qq plots**

Regional plots were generated with a mixture of home-made Python (v2.7) and R (v3.6.0) scripts. Briefly, given an input variant, we calculated linkage disequilibrium between the input variant and all the surrounding variants within a window of length defined by the user. Linkage disequilibrium was calculated in the 1000 Genomes samples of European ancestry. We used gene positions from RefSeq (release 93): in the case of multiple gene models for a given gene, we reported the model with the largest number of exons. We used recombination rates from HapMap II and chromatin states from ENCODE/Broad (15 states were grouped to highlight the predicted functional elements). As a reference genome we used GRCh37. Quantile–quantile (QQ) plots, Manhattan plots and exploration of genomic inflation factors were performed using the R package qqman.

**Functional annotation**

We used FUMA1 (Functional Mapping and Annotation of Genome-Wide Association Studies, v1.3.4c) for interpreting SNP-trait associations. FUMA is an online platform that annotates GWAS findings and prioritises the most likely causal SNPs and genes using information from 18 biological data repositories and tools. As input we used the summary statistics of our meta-GWAS. Gene prioritisation is based on a combination of positional mapping, expression quantitative trait loci (eQTL) mapping and chromatin interaction mapping. Functional annotation was performed by applying methodology similar to that described by Jansen et al.2. We refer to the original publication for details on the methods and repositories of FUMA1.

*Annotation of candidate SNPs in genomic risk loci.*

The functional effects of SNPs on genes were obtained by performing ANNOVAR3 using Ensembl genes (build 85). Note that SNPs can be annotated to more than one gene in the case of intergenic SNPs, which are annotated to the two closest up- and downstream genes. CADD scores4, RegulomeDB scores5 and the 15-core chromatin state6 are annotated to all SNPs in 1000G phase 3 by matching chromosome, position, reference and alternative alleles.

Positional mapping maps SNPs to genes based on physical distance (within a 10 Kb window) from known protein-coding genes in the human reference assembly (GRCh37/hg19). Two scores of intolerance to functional mutations are annotated: the probability of being loss-of-function intolerant7 (pLI) and the non-coding residual variation intolerance score8 (ncRVIS).

eQTL mapping maps significant SNPs and SNPs in LD of them to genes with which they show a significant eQTL association or where the same, allelic variation at the SNP is associated with the expression level of that gene. eQTL mapping uses information from 45 tissue types in 3 data repositories (GTEx9 v6, Blood eQTL browser10, BIOS QTL browser11) and is based on cis-eQTLs, which can map SNPs to genes up to 1 Mb apart. We used a false discovery rate of 0.05 to define significant eQTL associations.

Chromatin interaction mapping was performed to map SNPs to genes when there was a three-dimensional DNA–DNA interaction between the SNP region and another gene region.

*MAGMA for gene analysis and gene set analysis.*

FUMA uses input GWAS summary statistics to compute gene-based P-values (gene analysis) and gene set P-value (gene set analysis) using the MAGMA12 tool. For gene analysis, the gene-based P-value is computed for protein-coding genes by mapping SNPs to genes if SNPs are located within the genes. For gene set analysis, the gene set P-value is computed using the gene-based P-value for 4,728 curated gene sets (including canonical pathways) and 6,166 GO terms obtained from MsigDB v5.2. For both analyses, the default MAGMA setting (the SNP-wise model for gene analysis and the competitive model for gene set analysis) were used, and the Bonferroni correction (gene) or FDR (gene-set) was used to correct for multiple testing.

*Gene expression data set and gene set enrichment test.*

The GENE2FUNC process annotates the prioritised genes in a biological context and visualises their tissue-specific expression patterns as an interactive heatmap based on GTEx v6 RNA-seq data for each gene. Normalised gene expression data (RPKM, Read Per Kilobase per Million) from the GTEx portal v68 for 53 tissue types were processed. To test for the overrepresentation of biological functions, a list of prioritised genes was tested against gene sets obtained from MsigDB and WikiPathways using hypergeometric tests. FUMA reported gene sets with an adjusted P-value of ≤ 0.05 and the number of genes that overlap with the gene set > 1 by default. Multiple testing correction was performed per data source of tested gene sets.

**Follow-up Datasets**

We present a short description of 16 cohorts, often including multiple sites or studies, that contributed to this manuscript (Supplementary Table 3).

*The European Alzheimer's Disease DNA BioBank dataset (EADB)* contains 14,503 Alzheimer’s disease (AD) cases and 18,992 controls analysed mainly from 3 nodes: EADB-France, EADB-Germany and EADB-Netherlands.

EADB-France node

In the France node (***EADB-nodeFRA)***, samples were collected from 8 countries: Belgium (1,171 AD cases and 1,510 controls), Finland (1,219 AD cases and 2,018 controls), France (2,355 AD cases and 4,170 controls), Greece (568 AD cases and 112 controls), Italy (3,430 AD cases and 1,418 controls), Spain (1,607 AD cases and 1,376 controls), Sweden (1,566 AD cases and 1,376 controls) and United Kingdom (2,700 AD cases and 2,601 controls). After processing the data, they were 10,374 AD cases and 11,321 controls.

EADB-German node

In the German node, samples were collected from 7 countries: Germany, Greece, Switzerland, Portugal, Spain, Belgium and Bulgaria. To avoid problems of population stratification, each country with AD and controls was analysed separately.

***EADB-GER*** was configured by 7 data sets from Germany comprising 1,228 AD cases and 1799 controls: the VOGEL study, the Heidelberg/Mannheim clinical memory sample, the PAGES study, the Technische Universität München study, The Göttingen Universität study, German Dementia Competence Network cohort (DCN), German study on aging, cognition and dementia cohort (AgeCoDe) and Ludwig-Maximilians-Universität (LMU).

The VOGEL study*:* The Vogel study is a prospective, observational, long-term, follow-up study with three time points of investigation within 6-8 years. This cohort includes dementia and healthy subjects. Residents of the city of Würzburg born between 1936 and 1941 were recruited. Every participant underwent physical, psychiatric, and laboratory examinations, and performed an intense neuropsychological testing as well as VSEP and NIRS according to the published procedures. 604 subjects were included. Mean age of the participants was 73.9 ± 1.55 years.

Heidelberg/Mannheim memory clinic sample: This cohort includes 61 subjects from whom 40 MCI patients were recruited and assessed between 2012 to 2016. Some of those patients converted to dementia by AD or other dementias.

The PAGES study: This study includes 301 subjects. Patients with AD were recruited at the memory clinic of the Department of Psychiatry, University of Munich, Germany. Participants in whom dementia associated with AD was diagnosed fulfilled the criteria for probable AD, according to the NINCDS-ADRDA criteria. The control group included participants who were randomly selected from the general population of Munich. Controls who had a disease of the central nervous system or a psychotic disorder or who had a first-degree relative with a psychotic disorder were excluded.

The Technische Universität München study: This cohort includes 359 healthy, AD and other dementias patients recruited from the Centre for Cognitive Disorders. All participants provided written informed consent. Biobank was submitted to the ethic committee of the Technical University of Munich, School of Medicine, Munich, Germany that raised no objections and approved the biobank (reference number 347-14).

The Göttingen Universität study: This study includes 111 in- and out-patients with a healthy or AD dementia status from the department of psychiatry of the University of Göttingen. The study ethical statement was provided locally at the Göttingen University Medical Centre.

German Dementia Competence Network cohort (DCN): The individuals from DCN cohort were recruited from 14 university hospital memory clinics across Germany between 2003 and 200513. The study was approved by the respective ethics committees, and written informed consent was obtained from all participants prior to inclusion.

German study on aging, cognition and dementia cohort (AgeCoDe): The AgeCoDe study is a general practice (GP) registry-based longitudinal study in elderly individuals that recruited patients aged 75 years and above in six German cities from 2003 to 200414. The study was approved by the respective ethics committees, and written informed consent was obtained from all participants prior to inclusion.

***EADB-SWI***was configured by 2 data sets from Switzerland and Austria totalling 181 AD cases and 401 controls: the Lausanne study and VITA study.

The Lausanne study: This study included 137 community dwelling participants aged 55+, with cognitive impairment (memory clinic patients with MCI, dementia) or normal cognition (recruited by advertisement, word of mouth). The study ethical statement was provided locally at the Department of Psychiatry, Geneva University Centre, Switzerland.

The VITA study: This is a Longitudinal study of 606 individuals (Vienna, Austria) who were 75 years old in year 2000, followed up every 30 months up to 90 months. This cohort includes dementia and healthy subjects. All participants of the VITA study gave a written, informed consent. The study conformed to the latest version of the Declaration of Helsinki and was approved by the Ethics Committee of the City of Vienna, Austria.

***EADB-GRE***was configured by the HELIAD study from Greece comprising 49 AD cases and 1150 controls. HELIAD is a population-based, multidisciplinary, collaborative study designed to estimate, in the Greek population over the age of 64 years, prevalence and incidence of MCI, AD, other forms of dementia and other neuropsychiatric conditions of aging and to investigate associations between nutrition and cognitive dysfunction or age-related neuropsychiatric diseases. The participants were selected through random sampling from the records of 2 Greek municipalities, Larissa and Marousi. All participants signed an informed consent in Greek.

***EADB-POR***was configured by the Lisbon study from Portugal totalling 78 AD cases and 74 controls. This cohort was recruited in 2008-2009 to investigate connections between oxidative stress and lipid dyshomeostasis in AD. The project includes 190 subjects and was approved by the local ethics committee and all participants provided written informed consent. This study includes healthy and dementia by AD subjects.

***EADB-F.ACE/BBB*** represents the Spanish samples. This sub-cohort configured an extra and independent dataset comprising a total of 1,008 AD cases and 1,386 controls. A fraction of the AD cases (n = 332) were pathological, confirmed by Biobank-Hospital Clínic-Institut d’Investigacions Biomèdiques August Pi i Sunyer15 (IDIBAPS; Barcelona, Spain; URL: [www.clinicbiobanc.org](http://www.clinicbiobanc.org)) following the guidelines and approval of the local ethics committee. The remaining (n = 676) were diagnosed based on clinical criteria from Fundació ACE. These individuals were recruited following an methodology identical to that previously described for the GR@ACE discovery cohort.

EADB-Netherlands node

The ***EADB–NL*** dataset contains 1,895 AD cases and 2,865 controls recruited by three studies: the Amsterdam Dementia Cohort (ADC), the Longitudinal Aging Study of Amsterdam cohort (LASA) and the 100-Plus study. The Medical Ethics Committee of the VU University Medical Centre (METC) approved the three studies. All participants and/or their legal guardians gave written informed consent for participation in clinical and genetic studies.

The 100-Plus study includes Dutch-speaking individuals who (i) can provide official evidence for being aged 100 years or older, (ii) self-report to be cognitively healthy, which is confirmed by a proxy, (iii) consent to the donation of a blood sample, (iv) consent to (at least) two home visits from a researcher and (v) consent to undergo an interview and neuropsychological test battery16.

LASA is an ongoing longitudinal study of older adults in the Netherlands initiated in 1991, and represents a sample of individuals aged 55–85 years from the Netherlands17,18.

The ADC comprises patients who visit the memory clinic of the VU University Medical Centre, the Netherlands. The diagnosis of probable AD is based on the clinical criteria formulated by the National Institute of Neurological and Communicative Disorders and Stroke–AD and Related Disorders Association (NINCDS–ADRDA) and based on the National Institute of Aging–Alzheimer’s Association (NIA–AA)19,20.

*PGC–ALZ:* The Alzheimer workgroup initiative of the Psychiatric Genomic Consortium was configured by three non-public datasets with 2,737 AD cases and 14,800 controls (the Norwegian DemGene network, the Swedish Twin Studies of Aging and TwinGene). Further details can be found in Jansen et al.2.

Briefly, the ***DemGene*** Network is a Norwegian network of clinical sites collecting cases from Memory Clinics based on standardised examination of cognitive, functional and behavioural measures and data on the progression of most patients. The Norwegian DemGene Network includes 2,224 cases and 1,855 healthy controls from different studies described elsewhere2. The cases were diagnosed according to the recommendations from the National Institute on Aging–Alzheimer’s Association (NIA/AA), the NINCDS-ADRDA criteria or the ICD-10 research criteria. The controls were screened with a standardised interview and cognitive tests. Individuals from the DemGene Study were genotyped using the Human Omni Express-24 v.1.1 (Illumina Inc., San Diego, CA, USA) at deCODE Genetics (Reykjavik, Iceland).

***The Swedish Twin Studies of Aging (STSA)*** (n cases = 398, n controls = 1,079) includes three sub-studies of aging within the Swedish Twin Registry. Informed consent was obtained from all participants, and the studies were approved by the Regional Ethics Board in Stockholm and the Institutional Review Board at the University of Southern California. DNA was extracted from blood samples and genotyped using Illumina Infinium PsychArray. AD patients were diagnosed as part of the studies according to the NINCDS/ADRDA criteria.

***TwinGene***:This is a population-based study of older twins drawn from the Swedish Twin Registry. Written informed consent was obtained from all participants and the study was approved by the Regional Ethics Board in Stockholm. DNA was extracted from blood samples and genotyped using Illumina Human OmniExpress.

***GR@ACE* *replication***:We also configured an extra and independent dataset comprising 516 AD cases and 686 controls. This dataset was incorporated only for replication purposes. The GR@ACE dataset was recruited following a methodology identical to that described for the GR@ACE discovery cohort.

***Clinical AD Sweden, and the Gothenburg Birth Cohort Studies (GBCS)***: The AD sample consists of AD cases recruited at memory-clinics in different Swedish Cities21. The study was approved by the local Ethical Commissions at the respective academic center and the tenets of the Declaration of Helsinki were followed. In the present study the AD and GBCS cohort contributed to 514 AD cases and 3,467 controls.

The Gothenburg Birth Cohort Studies (controls) consist of data from four studies which recruited individuals representative of the Swedish population. The sample with genetic data includes individuals from “Prospective Population Study of Women” (PPSW), a study of women who have been followed since 1968 (age at inclusion 38–60)22; individuals born in 1930 and 1944 from the H70 study, which includes longitudinally followed samples recruited at age 7023,24; individuals born in 1923–24 from the H85 study, which includes longitudinally followed samples recruited at age 8525 and individuals from the 95-Plus study, recruited between 1996 and 2012 and followed until death26. The studies were approved by the Regional Ethical Review Board in Gothenburg, and informed consent was obtained from all participants and/or their relatives in cases of dementia.

***The Neocodex–Murcia study (NxC)***:The study includes 324 sporadic AD patients and 754 controls of unknown cognitive status from the Spanish general population collected by Neocodex27,28. AD patients were diagnosed as having possible or probable AD in accordance with the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the AD and Related Disorders Association (NINCDS–ADRDA)29.

***The AddNeuroMed Study (ADDN)***: This was a public-private partnership for biomarker discovery and replication in AD30–32. It was a multi-centre study in Europe, with the first patient enrolled in January 2006 and the last in February 2008. The study protocol was planned for a baseline assessment visit with follow-ups every three months for the first year, then annual visits that continued through 2013. The study enrolled a total of 258 AD, 257 MCI and 266 controls, but not all had complete data at each assessment. In the present study we included 450 cases and 187 controls. This dataset was downloaded from Synapse33.

***Sydney MAS study (MAS)***:This is a longitudinal study investigating mild cognitive impairment, related syndromes and age-related cognitive change. Older adults (70–90 years old) were randomly recruited from the community in Sydney, Australia (n = 1037). An extensive interview was undertaken, and questionnaire data collected, including demographics, cognitive performance and medical history. The majority of participants provided a blood sample for genetic analysis. Neuroimaging was performed on a subset of participants. Ethics approval for the study was provided by the University of New South Wales and the Illawarra Area Health Service Human Research Ethics Committees. All participants provided written informed consent to join the study. More information is provided in Sachdev et al34. In the present study we included 43 cases and 215 controls.

***Supplementary results***

**Functional interpretation of new meta-GWAS significant signals.**

To link the observed variants to genes and functional motifs in their genomic regions, we applied different strategies implemented on the FUMA platform (see supplementary methods).

*Pathway annotation*

We performed gene-set analysis for curated biological pathways, and 11 gene sets were significantly associated with AD risk: Roversi glioma copy number up (*p* = 6.91×10-14), Protein lipid complex (*p* = 7.83×10-14), High density lipoprotein particle (*p* = 8.28×10-10), Regulation of amyloid precursor protein catabolic process (*p* = 9.22×10-9), Phospholipid efflux (*p* = 1.14×10-8), Reverse cholesterol transport (*p* = 2.91×10-8), Plasma lipoprotein particle clearance (*p* = 7.38×10-8), Protein lipid complex subunit organisation (*p* = 3.66×10-7), Protein lipid complex assembly (*p* = 1.23×10-6), Regulation of plasma lipoprotein particle levels (*p* = 2.05×10-6) and High density lipoprotein particle remodelling (*p* = 2.07×10-6) (Supplementary Table 9), although part of the association signal was also attributable to the *APOE* gene.

***Supplementary Acknowledgements***

Additional support for EADB cohorts was provided by: Italian Ministry of Health (Ricerca Corrente); Ministero dell'Istruzione, dell'Università e della Ricerca–MIUR project “Dipartimenti di Eccellenza 2018–2022” to Department of Neuroscience “Rita Levi Montalcini”, University of Torino (IR), and AIRAlzh Onlus-ANCC-COOP (SB); Partly supported by “Ministero della Salute”, I.R.C.C.S. Research Program, Ricerca Corrente 2018-2020, Linea n. 2 “Meccanismi genetici, predizione e terapie innovative delle malattie complesse” and by the “5 x 1000” voluntary contribution to the Fondazione I.R.C.C.S. Ospedale “Casa Sollievo della Sofferenza”; and RF-2018-12366665, Fondi per la ricerca 2019 (Sandro Sorbi). Copenhagen General Population Study (CGPS): We thank staff and participants of the CGPS for their important contributions. Karolinska Institutet AD cohort: Dr. Graff and co-authors of the Karolinska Institutet AD cohort report grants from Swedish Research Council (VR) 2015-02926, 2018-02754, 2015-06799, Swedish Alzheimer Foundation, Stockholm County Council ALF and resarch school, Karolinska Institutet StratNeuro, Swedish Demensfonden, and Swedish brain foundation, during the conduct of the study. ADGEN: This work was supported by Academy of Finland (grant numbers 307866); Sigrid   Jusélius Foundation; the Strategic Neuroscience Funding of the University of Eastern Finland; EADB project in the JPNDCO-FUND program (grant number 301220). CBAS: Supported by the project no. LQ1605 from the National Program of Sustainability II (MEYS CR), Supported by Ministry of Health of the Czech Republic, grant nr. NV19-04-00270 (All rights reserved), Grant Agency of Charles University Grants No. 693018 and 654217; the Ministry of Health, Czech Republic―conceptual development of research organization, University Hospital Motol, Prague, Czech Republic Grant No. 00064203; the Czech Ministry of Health Project AZV Grant No. 16―27611A; and Institutional Support of Excellence 2. LF UK Grant No. 699012. CNRMAJ-Rouen: This study received fundings from the Centre National de Référence Malades Alzheimer Jeunes (CNRMAJ). The Finnish Geriatric Intervention Study for the Prevention of Cognitive Impairment and Disability (FINGER) data collection was supported by grants from the Academy of Finland, La Carita Foundation, Juho Vainio Foundation, Novo Nordisk Foundation, Finnish Social Insurance Institution, Ministry of Education and Culture Research Grants, Yrjö Jahnsson Foundation, Finnish Cultural Foundation South Osthrobothnia Regional Fund, and EVO/State Research Funding grants of University Hospitals of Kuopio, Oulu and Turku, Seinäjoki Central Hospital and Oulu City Hospital, Alzheimer's Research & Prevention Foundation USA, AXA Research Fund, Knut and Alice Wallenberg Foundation Sweden, Center for Innovative Medicine (CIMED) at Karolinska Institutet Sweden, and Stiftelsen Stockholms sjukhem Sweden. FINGER cohort genotyping was funded by EADB project in the JPND CO-FUND (grant number 301220). Research on the Belgian EADB cohort is funded in part by the Alzheimer Research Foundation (SAO-FRA), The Research Foundation Flanders (FWO), and the University of Antwerp Research Fund. FK is supported by a BOF DOCPRO fellowship of the University of Antwerp Research Fund. SNAC-K is financially supported by the Swedish Ministry of Health and Social Affairs, the participating County Councils and Municipalities, and the Swedish Research Council. BDR Bristol: We would like to thank the South West Dementia Brain Bank (SWDBB) for providing brain tissue for this study. The SWDBB is part of the Brains for Dementia Research programme, jointly funded by Alzheimer’s Research UK and Alzheimer’s Society and is supported by BRACE (Bristol Research into Alzheimer’s and Care of the Elderly) and the Medical Research Council. BDR Manchester: We would like to thank the Manchester Brain Bankfor providing brain tissue for this study. The Manchester Brain Bank is part of the Brains for Dementia Research programme, jointly funded by Alzheimer’s Research UK and Alzheimer’s Society. BDR KCL: Human post-mortem tissue was provided by the London Neurodegenerative Diseases Brain Bank which receives funding from the UK Medical Research Council and as part of the Brains for Dementia Research programme, jointly funded by Alzheimer’s Research UK and the Alzheimer’s Society. The CFAS Wales study was funded by the ESRC (RES-060-25-0060) and HEFCW as ‘Maintaining function and well-being in later life: a longitudinal cohort study’, (Principal Investigators: R.T Woods, L.Clare, G.Windle, V. Burholt, J. Philips, C. Brayne, C. McCracken, K. Bennett, F. Matthews). We are grateful to the NISCHR Clinical Research Centre for their assistance in tracing participants and in interviewing and in collecting blood samples, and to general practices in the study areas for their cooperation. MRC: We thank all individuals who participated in this study. Cardiff University was supported by the Alzheimer's Society (AS; grant RF014/164) and the Medical Research Council (MRC; grants G0801418/1, MR/K013041/1, MR/L023784/1) (R. Sims is an AS Research Fellow). Cardiff University was also supported by the European Joint Programme for Neurodegenerative Disease (JPND; grant MR/L501517/1), Alzheimer's Research UK (ARUK; grant ARUK-PG2014-1), the Welsh Assembly Government (grant SGR544:CADR), Brain’s for dementia Research and a donation from the Moondance Charitable Foundation. Cardiff University acknowledges the support of the UK Dementia Research Institute, of which J. Williams is an associate director. Cambridge University acknowledges support from the MRC. Patient recruitment for the MRC Prion Unit/UCL Department of Neurodegenerative Disease collection was supported by the UCLH/UCL Biomedical Centre and NIHR Queen Square Dementia Biomedical Research Unit. The University of Southampton acknowledges support from the AS. King's College London was supported by the NIHR Biomedical Research Centre for Mental Health and the Biomedical Research Unit for Dementia at the South London and Maudsley NHS Foundation Trust and by King's College London and the MRC. ARUK and the Big Lottery Fund provided support to Nottingham University. Alfredo Ramirez: Part of the work was funded by the JPND EADB grant (German Federal Ministry of Education and Research (BMBF) grant: 01ED1619A). German Study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe): This study/publication is part of the German Research Network on Dementia (KND), the German Research Network on Degenerative Dementia (KNDD; German Study on Ageing, Cognition and Dementia in Primary Care Patients; AgeCoDe), and the Health Service Research Initiative (Study on Needs, health service use, costs and health-related quality of life in a large sample of oldestold primary care patients (85+; AgeQualiDe)) and was funded by the German Federal Ministry of Education and Research (grants KND: 01GI0102, 01GI0420, 01GI0422, 01GI0423, 01GI0429, 01GI0431, 01GI0433, 01GI0434; grants KNDD: 01GI0710, 01GI0711, 01GI0712, 01GI0713, 01GI0714, 01GI0715, 01GI0716; grants Health Service Research Initiative: 01GY1322A, 01GY1322B, 01GY1322C, 01GY1322D, 01GY1322E, 01GY1322F, 01GY1322G). VITA study: The support of the Ludwig Boltzmann Society and the AFI Germany have supported the VITA study. The former VITA study group should be acknowledged: W. Danielczyk, G. Gatterer, K Jellinger, S Jugwirth, KH Tragl, S Zehetmayer. Vogel Study: This work was financed by a research grant of the ‘‘Vogelstiftung Dr. Eckernkamp’’. HELIAD study: This study was supported by the grants: IIRG-09-133014 from the Alzheimer’s Association, 189 10276/8/9/2011 from the ESPA-EU program Excellence Grant (ARISTEIA) and the ΔΥ2β/οικ.51657/14.4.2009 of the Ministry for Health and Social Solidarity (Greece). Biobank Department of Psychiatry, UMG: Prof. Jens Wiltfang is supported by an Ilídio Pinho professorship and iBiMED (UID/BIM/04501/2013), and FCT project PTDC/DTP\_PIC/5587/2014 at the University of Aveiro, Portugal. Lausanne study: This work was supported by grants from the Swiss National Research Foundation (SNF 320030\_141179). PAGES study: Harald Hampel is an employee of Eisai Inc. During part of this work he was supported by the AXA Research Fund, the “Fondation partenariale Sorbonne Université” and the “Fondation pour la Recherche sur Alzheimer”, Paris, France. Mannheim, Germany Biobank: Department of geriatric Psychiatry, Central Institute for Mental Health, Mannheim, University of Heidelberg, Germany. Genotyping for the Swedish Twin Studies of Aging was supported by NIH/NIA grant R01 AG037985. Genotyping in TwinGene was supported by NIH/NIDDK U01 DK066134. WvdF is recipient of Joint Programming for Neurodegenerative Diseases (JPND) grants PERADES (ANR-13-JPRF-0001) and EADB (733051061). Gothenburg Birth Cohort (GBC) Studies: We would like to thank UCL Genomics for performing the genotyping analyses. The studies were supported by The Stena Foundation, The Swedish Research Council (2015-02830, 2013-8717), The Swedish Research Council for Health, Working Life and Wellfare (2013-1202, 2005-0762, 2008-1210, 2013-2300, 2013- 2496, 2013-0475), The Brain Foundation, Sahlgrenska University Hospital (ALF), The Alzheimer’s Association (IIRG-03-6168), The Alzheimer’s Association Zenith Award (ZEN-01-3151), Eivind och Elsa K:son Sylvans Stiftelse, The Swedish Alzheimer Foundation. Clinical AD, Sweden: We would like to thank UCL Genomics for performing the genotyping analyses. Barcelona Brain Biobank: Brain Donors of the Neurological Tissue Bank of the Biobanc-Hospital Clinic-IDIBAPS and their families for their generosity. Hospital Clínic de Barcelona Spanish Ministry of Economy and Competitiveness-Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea, “Una manera de hacer Europa” grants (PI16/0235 to Dr. R. Sánchez-Valle and PI17/00670 to Dr. A.Antonell). AA is funded by Departament de Salut de la Generalitat de Catalunya, PERIS 2016-2020 (SLT002/16/00329). Sydney Memory and Ageing Study (Sydney MAS): We gratefully acknowledge and thank the following for their contributions to Sydney MAS: participants, their supporters and the Sydney MAS Research Team (current and former staff and students). Funding was awarded from the Australian National Health and Medical Research Council (NHMRC) Program Grants (350833, 568969, 109308). AddNeuroMed consortium was led by Simon Lovestone, Bruno Vellas, Patrizia Mecocci, Magda Tsolaki, Iwona Kłoszewska, Hilkka Soininen. This work was supported by InnoMed (Innovative Medicines in Europe), an integrated project funded by the European Union of the Sixth Framework program priority (FP6-2004- LIFESCIHEALTH-5). Oviedo: This work was partly supported by Grant from Fondo de Investigaciones Sanitarias-Fondos FEDER EuropeanUnion to Victoria Alvarez PI15/00878. Pascual Sánchez-Juan is supported by CIBERNED and Carlos III Institute of Health, Spain (PI08/0139, PI12/02288, and PI16/01652), jointly funded by Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea, “Una manera de hacer Europa”. Project MinE: The ProjectMinE study was supported by the ALS Foundation Netherlands and the MND association (UK) (Project MinE, www.projectmine.com). The SPIN cohort: We are indebted to patients and their families for their participation in the “Sant Pau Initiative on Neurodegeneration cohort”, at the Sant Pau Hospital (Barcelona). This is a multimodal research cohort for biomarker discovery and validation that is partially funded by Generalitat de Catalunya (2017 SGR 547 to JC), as well as from the Institute of Health Carlos III-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER- “Una manera de Hacer Europa”) (grants PI11/02526, PI14/01126, and PI17/01019 to JF; PI17/01895 to AL), and the Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas programme (Program 1, Alzheimer Disease to AL). We would also like to thank the Fundació Bancària Obra Social La Caixa (DABNI project) to JF and AL; and Fundación BBVA (to AL), for their support in funding this follow-up study. Adolfo López de Munain is supported by Fundación Salud 2000 (PI2013156) and Diputación Foral de Gipuzkoa (Exp.114/17).

***References***

1. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nat. Commun.* (2017). doi:10.1038/s41467-017-01261-5

2. Jansen, I. E. *et al.* Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. *Nat. Genet.* **51**, 404–413 (2019).

3. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* **38**, e164–e164 (2010).

4. Kircher, M. *et al.* A general framework for estimating the relative pathogenicity of human genetic variants. *Nat. Genet.* **46**, 310–5 (2014).

5. Boyle, A. P. *et al.* Annotation of functional variation in personal genomes using RegulomeDB. *Genome Res.* **22**, 1790–1797 (2012).

6. Ernst, J. & Kellis, M. ChromHMM: automating chromatin-state discovery and characterization. *Nat. Methods* **9**, 215–216 (2012).

7. Lek, M. *et al.* Analysis of protein-coding genetic variation in 60,706 humans. *Nature* **536**, 285–291 (2016).

8. Petrovski, S. *et al.* The Intolerance of Regulatory Sequence to Genetic Variation Predicts Gene Dosage Sensitivity. *PLOS Genet.* **11**, e1005492 (2015).

9. The GTEx Consortium *et al.* The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans. *Science (80-. ).* (2015). doi:10.1126/science.1262110

10. Westra, H.-J. *et al.* Systematic identification of trans eQTLs as putative drivers of known disease associations. *Nat. Genet.* **45**, 1238–1243 (2013).

11. Zhernakova, D. V *et al.* Identification of context-dependent expression quantitative trait loci in whole blood. *Nat. Genet.* **49**, 139–145 (2017).

12. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-Set Analysis of GWAS Data. *PLoS Comput. Biol.* (2015). doi:10.1371/journal.pcbi.1004219

13. Kornhuber, J. *et al.* Early and Differential Diagnosis of Dementia and Mild Cognitive Impairment. *Dement. Geriatr. Cogn. Disord.* **27**, 404–417 (2009).

14. Luck, T. *et al.* Mild Cognitive Impairment in General Practice: Age-Specific Prevalence and Correlate Results from the German Study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe). *Dement. Geriatr. Cogn. Disord.* **24**, 307–316 (2007).

15. Grau-Rivera, O. *et al.* Clinicopathological Correlations and Concomitant Pathologies in Rapidly Progressive Dementia: A Brain Bank Series. *Neurodegener. Dis.* (2015). doi:10.1159/000439251

16. Holstege, H. *et al.* The 100-plus Study of cognitively healthy centenarians: rationale, design and cohort description. *Eur. J. Epidemiol.* (2018). doi:10.1007/s10654-018-0451-3

17. Huisman, M. *et al.* Cohort Profile: The Longitudinal Aging Study Amsterdam. *Int. J. Epidemiol.* **40**, 868–876 (2011).

18. Hoogendijk, E. O. *et al.* The Longitudinal Aging Study Amsterdam: cohort update 2016 and major findings. *Eur. J. Epidemiol.* **31**, 927–945 (2016).

19. van der Flier, W. M. *et al.* Optimizing patient care and research: the Amsterdam Dementia Cohort. *J. Alzheimer’s Dis. JAD* **41**, 313–327 (2014).

20. Van Der Flier, W. M. & Scheltens, P. Amsterdam dementia cohort: Performing research to optimize care. *Journal of Alzheimer’s Disease* (2018). doi:10.3233/JAD-170850

21. Zetterberg, H. *et al.* Clinical proteomics in neurodegenerative disorders. *Acta Neurologica Scandinavica* (2008). doi:10.1111/j.1600-0404.2007.00985.x

22. Bengtsson, C. *et al.* THE STUDY OF WOMEN IN GOTHENBURG 1968-1969 -A POPULATION STUDY. *Acta Med. Scand.* **193**, 311–318 (2009).

23. Skoog, I. *et al.* A 9-Year Prospective Population-Based Study on the Association Between the APOE\*E4 Allele and Late-Life Depression in Sweden. *Biol. Psychiatry* **78**, 730–736 (2015).

24. Zettergren, A. *et al.* The ACE Gene Is Associated with Late-Life Major Depression and Age at Dementia Onset in a Population-Based Cohort. *Am. J. Geriatr. Psychiatry* (2017). doi:10.1016/j.jagp.2016.06.009

25. Skoog, I. *et al.* Decreasing prevalence of dementia in 85-year olds examined 22 years apart: the influence of education and stroke. *Sci. Rep.* **7**, 6136 (2017).

26. Skoog, J. *et al.* A Longitudinal Study of the Mini-Mental State Examination in Late Nonagenarians and Its Relationship with Dementia, Mortality, and Education. *J. Am. Geriatr. Soc.* **65**, 1296–1300 (2017).

27. Gayán, J. *et al.* Genetic structure of the Spanish population. *BMC Genomics* **11**, 326 (2010).

28. Antúnez, C. *et al.* The membrane-spanning 4-domains, subfamily A (MS4A) gene cluster contains a common variant associated with Alzheimer’s disease. *Genome Med.* **3**, 33 (2011).

29. McKhann, G. *et al.* Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group\* under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. *Neurology* **34**, 939–939 (1984).

30. Proitsi, P. *et al.* Genetic predisposition to increased blood cholesterol and triglyceride lipid levels and risk of Alzheimer disease: a Mendelian randomization analysis. *PLoS Med.* **11**, e1001713 (2014).

31. Lourdusamy, A. *et al.* Identification of *cis-* regulatory variation influencing protein abundance levels in human plasma. *Hum. Mol. Genet.* **21**, 3719–3726 (2012).

32. Furney, S. J. *et al.* Genome-wide association with MRI atrophy measures as a quantitative trait locus for Alzheimer’s disease. *Mol. Psychiatry* **16**, 1130–8 (2011).

33. Alzheimers Disease - Community Portal - syn2790911. Available at: https://www.synapse.org/#!Synapse:syn2790911/wiki/70465. (Accessed: 18th October 2019)

34. Sachdev, P. S. *et al.* The Sydney Memory and Ageing Study (MAS): methodology and baseline medical and neuropsychiatric characteristics of an elderly epidemiological non-demented cohort of Australians aged 70–90 years. *Int. Psychogeriatrics* **22**, 1248–1264 (2010).